Sign in
ONCS Stock Price, Chart, Stats & News
OncoSec Medical Incorporated
Save
1.65M
Market cap
–
Current P/E
–
Forward P/E
ONCS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 8.89% |
ROA | -156.23% |
ROE | -154.68% |
D/E | 1.01x |
Interest coverage ratio | -1768.80x |
ONCS valuation
P/E | – |
P/S | – |
P/B | 0.08x |
P/CF | -0.02x |
P/FCF | -0.05x |
P/OCF | -0.02x |
PEG | -0.00x |
EV multiple | -0.21x |
About
OncoSec Medical Incorporated is a late-stage immuno-oncology firm dedicated to creating, advancing, and bringing to market DNA-based therapeutics designed for direct injection into tumors. These therapies aim to activate and amplify the body's anti-cancer immune responses. Its primary therapeutic candidate, ImmunoPulse IL-12 (also known as TAVO), employs an electroporation device to administer DNA encoding interleukin-12 directly into tumors, thereby counteracting the tumor's immunosuppressive environment.
Similar securities
Based on sector and market capitalization
Report issue